Carriage of Streptococcus pneumoniae 3 Years after Start of Vaccination Program, the Netherlands


Published in: Emerging Infectious Diseases

DOI: 10.3201/eid1704101115

Citation for published version (APA):
Carriage of *Streptococcus pneumoniae* 3 Years after Start of Vaccination Program, the Netherlands


To evaluate the effectiveness of the 7-valent pneumococcal conjugate vaccine (PCV7) program, we conducted a cross-sectional observational study on nasopharyngeal carriage of *Streptococcus pneumoniae* 3 years after implementation of the program in the Netherlands. We compared pneumococcal serotypes in 329 prebooster 11-month-old children, 330 fully vaccinated 24-month-old children, and 324 parents with age-matched pre-PCV7 (unvaccinated) controls (ages 12 and 24 months, n = 319 and n = 321, respectively) and 296 of their parents.

PCV7 serotype prevalences before and after PCV7 implementation, respectively, were 38% and 8% among 11-month-old children, 36% and 4% among 24-month-old children, and 8% and 1% among parents. Non-PCV7 serotype prevalences were 29% and 39% among 11-month-old children, 30% and 45% among 24-month-old children, and 8% and 15% among parents, respectively; serotypes 11A and 19A were most frequently isolated. PCV7 serotypes were largely replaced by non-PCV7 serotypes. Disappearance of PCV7 serotypes in parents suggests strong transmission reduction through vaccination.

*Streptococcus pneumoniae* (pneumococcus) is a major cause of respiratory and invasive disease worldwide, particularly in children <5 years of age and elderly persons (1). All pneumococcal disease is preceded by nasopharyngeal colonization (2). To date, slightly >90 serotypes have been identified. Young children, among whom nasopharyngeal carriage rates are highest, are the main reservoir for pneumococcal spread in families and the community (3).

In the United States and other industrialized countries, widespread use of the 7-valent pneumococcal conjugate vaccine (PCV7) (Prevenar; Pfizer, New York, NY, USA) for children has led to a dramatic decline in PCV7-serotype invasive pneumococcal disease (IPD), not only in vaccinated children (4) but also in unvaccinated persons of all ages (5,6). This indirect effect has substantially contributed to favorable cost-effectiveness estimates of the vaccination program (7,8). However, shifts toward nasopharyngeal carriage of non-PCV7 serotypes may eventually counterbalance the direct and indirect benefits of the vaccine, assuming that non-PCV7 serotypes will display similar disease potential (9-12). Early evaluation of the effect of pneumococcal vaccination on serotype distribution in disease is hampered by the relative infrequency of IPD and the difficulty of identifying causative agents in respiratory diseases such as pneumonia or in otitis media. Therefore, surveillance of nasopharyngeal carriage of pneumococci in vaccinated and in unvaccinated persons provides another useful tool for monitoring how vaccination affects circulating pneumococcal serotypes.

In the Netherlands, as part of the national immunization program (NIP), vaccination with PCV7 was introduced for all infants born after March 31, 2006, in a 3+1 schedule of vaccinations at 2, 3, 4, and 11 months with no catch-up campaign. To evaluate how this PCV7 vaccination program affected prevalence of pneumococcal serotypes after 3 years, we conducted a cross-sectional observational...
study of nasopharyngeal carriage of pneumococci, and we compared data from vaccinated children and their parents with data from age-matched pre-PCV7 (unvaccinated) controls.

Methods

Study Design

In 2009, after PCV7 vaccination had been conducted for 3 years, we examined nasopharyngeal swabs for pneumococcal carriage from 2 age cohorts: 1) healthy 11-month-old children who had received 3 primary vaccinations according to the Dutch NIP but had not yet received the booster dose at 11 months of age or had had the booster dose within the week before sampling, 2) healthy 24-month-old children vaccinated according to the Dutch NIP. We also examined swabs from 1 parent each for the 24-month-old children. Exclusion criteria for children were known or suspected immunodeficiency, craniofacial or chromosomal abnormalities, coagulation disorders, use of anticoagulant medication, and having older siblings in the household who had received a pneumococcal conjugate vaccine. Parents were excluded if they had a bleeding disorder or used anticoagulant medication. The study (NL24116.000.08) was approved by an acknowledged national ethics committee in the Netherlands. The study was conducted in accordance with the European Statements for Good Clinical Practice.

Data from the vaccinated children cohorts were compared with data from pre-PCV7 control children and their parents derived from a longitudinal, randomized, controlled trial (NCT00189020) that had started in the Netherlands well before national PCV7 implementation for infants. In that trial, children had been included at the age of 6 weeks from July 2005 through February 2006 and were followed-up until 24 months of age. Nasopharyngeal swabs were obtained from children at 12 and 24 months of age and from 1 parent of each of the 24-month-old children; results have been described (13).

Nasopharyngeal Swabs

Trained study personnel collected the nasopharyngeal swabs from children and parents by using a flexible, sterile, dry cotton–wool swab transnasally, according to World Health Organization standard procedures (14). Also, a transoral nasopharyngeal swab was collected from parents because the pneumococcal yield is known to be higher for adults when both areas are swabbed (15). Transoral swabs of the directly observed posterior pharynx were collected on a rigid cotton–wool swab. All swabs in both studies were processed according to the same study procedures by the same laboratory for microbiology as described (13). Briefly, swabs were cultured for 

then 1 pneumococcal colony per plate was subcultured and serotyped by the capsular swelling method (Quellung reaction). All serotype 6A isolates were submitted to the National Reference Laboratory of Bacterial Meningitis (Academic Medical Center, Amsterdam) for further discrimination between 6A and the newly discovered serotype 6C by PCR with primers 5106 and 1301 and primers 6C-fwd and 6C-rev (16). Results were confirmed by the Quellung reaction with newly available antisera to identify 6C serotype (Statens Serum Institute, Copenhagen, Denmark). In a post hoc analysis, all serotype 19A isolates from children were examined by the disk-diffusion method for susceptibility to azithromycin, erythromycin, and penicillin and were further tested by Etest (PDM Epsilometer; AB Biodisk, Solna, Sweden) and classified according to Clinical and Laboratory Standards Institute (M100-S20). Because oral antimicrobial drugs are the driving force for resistance in the community, susceptibility to penicillin was further classified according to breakpoints defined by the Clinical and Laboratory Standards Institute; isolates were considered penicillin susceptible (MIC ≤0.06 µg/mL), penicillin intermediately resistant (MIC 0.12–1.0 µg/mL), or penicillin resistant (MIC ≥2.0 µg/mL) (17).

Covariates

A questionnaire, completed by each participant at the time of nasopharyngeal sampling, was used to determine risk factors for nasopharyngeal carriage of pneumococci. The questionnaire asked about the following: age, sex, month of sampling, presence of siblings in the household, daycare attendance, passive smoke exposure indoors, clinical signs of a respiratory tract infection at the time of sampling, antimicrobial drug use within 1 month before the sample was taken, and active smoking of the participating parent.

Statistical Analyses

Data on 

were compared with data from the pre-PCV7 control cohort at age 12 months (n = 319) and 24 months (n = 321) and the parents of the 24-month-old children (n = 296) in which children were enrolled as described previously (13). According to protocol, the primary study outcome was defined as the prevalence of any of the PCV7 serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) and any of the non-PCV7 serotypes (all other pneumococcus serotypes including nontypeable isolates) in children. On the basis of previous trial results (13), we expected that the smallest difference we would detect would be prevalence of non-PCV7 serotypes at age 11 and 24 months with a 29% carriage rate in the pre-PCV7 control cohort and an estimated 40% in vaccinated children. Therefore, before conducting the study, we estimated that a minimum sample size of ≈330 children in
RESEARCH

each group was needed to detect this difference with 80% power with a 2-sided α of 0.05. Differences in prevalence rates were statistically tested by using a 2-sided χ² or Fisher exact test, where appropriate. Multivariate analysis with binary logistic regression modeling was used to obtain adjusted estimates of the association between the outcomes and intervention as given by adjusted odds ratios (ORs) and their corresponding 95% confidence intervals (CIs).

**Results**

Three years after PCV7 implementation in the NIP for all newborns, parents of 11,005 children were invited to participate. A total of 1,045 (9.5%) parents were interested in participating, among which 892 families were assessed for eligibility; 153 families were not assessed because the enrollment target had already been achieved. Of the 892 families, 233 were excluded. The most frequent reason for exclusion was household presence of older siblings who had received a pneumococcal conjugate vaccine (78%). In total, 329 children 11 months of age and 330 children 24 months of age and 1 parent for each of the 24-month-old children (n = 324) were enrolled from February 9 through July 9, 2009.

The mean age of vaccinees was slightly lower (4 weeks at 11 months, and 1 week at 24 months of age; both p<0.001) than that of the pre-PCV7 controls. At 11 months, the proportion of siblings <5 years of age and the exposure to smoking indoors was lower for vaccinees (both p<0.001). At 24 months, the proportion of male participants and the proportion of children who had received antimicrobial drugs within 1 month before the swab was taken was higher among vaccinees (both p = 0.03). Also, the months of sampling differed between both studies (p<0.001; Table 1).

**Carriage of S. pneumoniae in Children**

Prevalence of any of the PCV7 serotypes was 38% among the pre-PCV7 controls compared with 8% among prebooster children at 11 months (OR 0.13, 95% CI 0.08–0.21) and 36% among the pre-PCV7 controls compared with 4% among children 24 months of age (OR 0.08, 95% CI 0.05–0.14) (Table 2). Prevalence rates for individual PCV7 serotypes were significantly lower among vaccinees except for the infrequently carried serotypes 18C (p = 0.45) and 4 (p = 0.49), which were almost absent before and after introduction of PCV7. Among children 24 months of age, serotype 6B had remained in only 2% of all vaccinated children, serotypes 19F and 18C in 1%, and all other PCV7 serotypes had almost disappeared (Table 3).

In contrast, corresponding prevalences of non-PCV7 serotypes were 29% and 39% among children 11 months of age (OR 1.59, 95% CI 1.15–2.21) and 30% and 45% among children 24 months of age (OR 1.88, 95% CI 1.36–2.59) in the pre-PCV7 and post-PCV7 cohorts, respectively (Table 2). In prebooster children, serotype 19A had become the most prevalent (10%), serotype 11A had remained stable at ≥4%, followed by 6A and 15B (each 3%). At 24 months, serotype 11A had become the most prevalent serotype (7%), followed closely by 19A (6%); proportions of each of these serotypes had doubled among the 24-month-old

---

Table 1. Characteristics of children and their parents before and 3 years after implementation of PCV7 vaccination program, the Netherlands*

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>11-mo-old children</th>
<th>24-mo-old children</th>
<th>Parents</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre-PCV7, n = 319</td>
<td>Post-PCV7, n = 324†</td>
<td>p value‡</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>156 (49)</td>
<td>181 (55)</td>
<td>0.12</td>
</tr>
<tr>
<td>Mean age (SD)</td>
<td>12.0 (0.3)</td>
<td>11.0 (0.3)</td>
<td>&lt;0.001§</td>
</tr>
<tr>
<td>Presence of siblings &lt;5 y of age</td>
<td>126 (40)</td>
<td>84 (26)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Day care attendance¶</td>
<td>208 (65)</td>
<td>226 (69)</td>
<td>0.35</td>
</tr>
<tr>
<td>Passive smoke exposure#</td>
<td>21 (7)</td>
<td>5 (2)</td>
<td>0.001</td>
</tr>
<tr>
<td>Signs of RTI**</td>
<td>95 (30)</td>
<td>95 (29)</td>
<td>0.80</td>
</tr>
<tr>
<td>Antimicrobial drug use††</td>
<td>20 (6)</td>
<td>24 (7)</td>
<td>0.60</td>
</tr>
<tr>
<td>Period of sampling Oct–Mar</td>
<td>149 (47)</td>
<td>82 (25)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Apr–Sep</td>
<td>170 (53)</td>
<td>247 (75)</td>
<td>NA</td>
</tr>
</tbody>
</table>

**Values are no. (%) except as indicated. PCV7, 7-valent pneumococcal conjugate vaccine; RTI, respiratory tract infection; NA, not applicable.
†Swabs taken just before booster vaccination at 11 mo of age or within 1 week after booster vaccination.
‡By χ² test or Fisher exact test (2-sided) where appropriate.
§By independent-samples t test.
¶Defined as >4 h/wk with ≥1 child from a different household.
#Defined as passive tobacco smoke exposure indoors to ≥1 cigar or cigarette during ≥5 d/wk.
**Defined by evaluation of parents.
††Defined as use of oral or intravenous antibiotics within 1 mo before sample was taken.
Table 2. Frequencies of nasopharyngeal carriage of *Streptococcus pneumoniae* in children and their parents before and 3 years after implementation of PCV7 vaccination program, the Netherlands*

<table>
<thead>
<tr>
<th>Participant s</th>
<th>Pre-PCV7, no. (%)</th>
<th>Post-PCV7, no. (%)†</th>
<th>OR‡ (95% CI)</th>
<th>aOR§ (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11-mo-old children</td>
<td>n = 319</td>
<td>n = 329</td>
<td>0.13 (0.08-0.21)</td>
<td>0.14 (0.09-0.23)</td>
</tr>
<tr>
<td>PCV7</td>
<td>122 (38)</td>
<td>25 (8)</td>
<td>1.59 (1.15-2.21)</td>
<td>1.64 (1.15-2.32)</td>
</tr>
<tr>
<td>Non-PCV7</td>
<td>92 (29)</td>
<td>129 (39)</td>
<td>0.43 (0.31-0.59)</td>
<td>0.44 (0.31-0.63)</td>
</tr>
<tr>
<td>All</td>
<td>214 (67)</td>
<td>154 (47)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>24-mo-old children</td>
<td>n = 321</td>
<td>n = 330</td>
<td>0.08 (0.05-0.14)</td>
<td>0.08 (0.05-0.15)</td>
</tr>
<tr>
<td>PCV7</td>
<td>114 (36)</td>
<td>14 (4)</td>
<td>1.88 (1.36-2.59)</td>
<td>2.01 (1.43-2.84)</td>
</tr>
<tr>
<td>Non-PCV7</td>
<td>97 (30)</td>
<td>148 (45)</td>
<td>0.50 (0.37-0.69)</td>
<td>0.51 (0.36-0.72)</td>
</tr>
<tr>
<td>All</td>
<td>211 (66)</td>
<td>162 (49)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parents</td>
<td>n = 296</td>
<td>n = 324</td>
<td>0.07 (0.02-0.29)</td>
<td>0.06 (0.01-0.26)</td>
</tr>
<tr>
<td>PCV7</td>
<td>25 (8)</td>
<td>2 (1)</td>
<td>1.93 (1.16-3.22)</td>
<td>1.98 (1.16-3.37)</td>
</tr>
<tr>
<td>Non-PCV7</td>
<td>25 (8)</td>
<td>49 (15)</td>
<td>0.92 (0.60-1.41)</td>
<td>0.90 (0.57-1.40)</td>
</tr>
<tr>
<td>All</td>
<td>50 (17)</td>
<td>51 (16)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*PCV7, all serotypes included in 7-valent pneumococcal conjugate vaccine; OR, odds ratio; CI, confidence interval; aOR, adjusted odds ratio; non-PCV7, all other serotypes not included in 7-valent pneumococcal conjugate vaccine; all, all pneumococcal serotypes.

†325/329 (99%) swabs are taken just before the booster vaccination at 11 mo of age and 4/329 (1%) children had received a booster vaccination within 1 week before the sample was obtained.

‡All ORs are based on comparison with pre-PCV7 control cohort.

§For children, ORs were adjusted by multivariate analysis for sex, month of sampling, presence of siblings in the household, day care attendance, passive smoke exposure indoors, symptoms of a respiratory tract infection during sampling, and antimicrobial drug use within 1 mo before the sample was taken. For parents, ORs were adjusted for sex, months of sampling, antimicrobial drug use within 1 month before the sample was taken, and active smoking.

Multivariate Analysis of Covariates

Unadjusted associations are shown as ORs in children and parents (Table 2). Multivariate analysis showed that associations after adjustments for some potential confounders did not differ from the unadjusted associations.

Discussion

Three years after NIP implementation of PCV7 for all newborns in the Netherlands, PCV7-serotype carriage of *S. pneumoniae* was reduced 80%-90% among vaccinated children at 11 and 24 months of age. Among parents of vaccinated children, carriage of PCV7 serotypes had almost disappeared. This impressive reduction of PCV7-serotype carriage in infants is larger than that observed in clinical trials, which showed 50%-60% reduction in PCV7 rates after conjugate vaccination, and should be attributed to herd effects (13,18,19). Herd effects would also account for the disappearance of PCV7 serotypes in parents. This large effect might in part be a result of a high pneumococcal vaccine uptake because 94.4% of all 2-year-old children in the Netherlands have been fully vaccinated (20). Our data confirm the major role of young infants in the transmission of pneumococci in the community.

Herd effects may also have contributed to the reported unexpectedly high reductions of otitis media (by 43%) (21) and all-cause pneumonia (by 33%) (22) in young children in the United States since PCV7 introduction. These reductions exceed overall vaccine efficacy found in randomized controlled trials: 6%-9% reduction of otitis media (9,23), and 4% reduction of all-cause pneumonia (24). However, a recent US study on community-acquired pneumonia (with radiographic confirmation) found no
RESEARCH

consistent reductions in pneumonia rates among children and adults, except for children <1 year of age (25). Whether this finding is the result of replacement disease by other nonvaccine pneumococcal serotypes, other pathogens, or other causes remains to be evaluated. Nasopharyngeal serotype replacement remains a potential drawback of vaccination with pneumococcal conjugate vaccines.

Increased rates of carriage of nonvaccine serotypes were also observed in this study. In vaccinated infants and their parents; serotypes 19A and 11A were the most frequently carried serotypes in the Netherlands. In the United States, multidrug resistant serotype 19A has become a frequent cause of IPD as well as of otitis media in children (26,27). There is ongoing debate about the actual role of PCV7 introduction and the increase in serotype 19A; antimicrobial drug pressure and secular trends have been emphasized (28). In our study, however, post hoc susceptibility testing of all 19A isolates showed a low prevalence of nonsusceptible strains among controls and vaccinees. In addition, our group previously reported a significant increase in serotype 19A carriage after PCV7 vaccinations in a study conducted in a randomized controlled setting (29), excluding secular trends and indicating a direct role of PCV7. A trend toward lower carriage rates of serotype 6A and higher carriage rates of serotype 6C was observed in both age groups, suggesting PCV7 cross-protection for serotype 6A but not for serotype 6C, in line with other carriage studies (30). However, serotypes 11A and 6C have not yet been reported as a frequent cause of IPD in the Netherlands (12).

Observed changes in prevalence of serotype carriage may not be entirely random but may be directly related to the serotype capsule size, which in turn is related to the polysaccharide composition and metabolic costs of the capsule for the bacterium (31). Pneumococci with larger capsules are more resistant against nonopsonic phagocytosis and more commonly colonize young children. Our results agree with results of Weinberger et al., which show a significant increase in carriage of highly encapsulated serotypes such as 19A, 11A, 10A, and 35F (31). Furthermore, the serotype-specific capsule has been shown to be a major factor in the potential to cause IPD, independent of genetic background and temporal or

Table 3. Frequencies of nasopharyngeal carriage of individual Streptococcus pneumoniae serotypes in children and their parents before and 3 years after implementation of PCV7 vaccination program, the Netherlands

<table>
<thead>
<tr>
<th>Serotype</th>
<th>11-mo-old children</th>
<th>24-mo-old children</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre-PCV7, n = 319</td>
<td>Post-PCV7, n = 329†</td>
</tr>
<tr>
<td></td>
<td>p value‡</td>
<td>p value‡</td>
</tr>
<tr>
<td>PCV7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19F</td>
<td>36 (11)</td>
<td>5 (2)</td>
</tr>
<tr>
<td>23F</td>
<td>34 (11)</td>
<td>6 (2)</td>
</tr>
<tr>
<td>6B</td>
<td>26 (8)</td>
<td>12 (4)</td>
</tr>
<tr>
<td>14</td>
<td>10 (3)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>9V</td>
<td>9 (3)</td>
<td>1 (0)</td>
</tr>
<tr>
<td>18C</td>
<td>6 (2)</td>
<td>1 (0)</td>
</tr>
<tr>
<td>4</td>
<td>1 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Non-PCV7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19A</td>
<td>5 (2)</td>
<td>32 (10)</td>
</tr>
<tr>
<td>11A</td>
<td>11 (3)</td>
<td>12 (4)</td>
</tr>
<tr>
<td>6A#</td>
<td>19 (6)</td>
<td>11 (3)</td>
</tr>
<tr>
<td>15B</td>
<td>3 (1)</td>
<td>10 (3)</td>
</tr>
<tr>
<td>15C</td>
<td>4 (1)</td>
<td>4 (1)</td>
</tr>
<tr>
<td>6C</td>
<td>5 (2)</td>
<td>8 (2)</td>
</tr>
<tr>
<td>22F</td>
<td>4 (1)</td>
<td>7 (2)</td>
</tr>
<tr>
<td>10A</td>
<td>1 (0)</td>
<td>6 (2)</td>
</tr>
<tr>
<td>16F</td>
<td>1 (0)</td>
<td>6 (2)</td>
</tr>
<tr>
<td>23B</td>
<td>5 (2)</td>
<td>5 (2)</td>
</tr>
<tr>
<td>35F</td>
<td>2 (1)</td>
<td>5 (2)</td>
</tr>
<tr>
<td>NT</td>
<td>1 (0)</td>
<td>6 (2)</td>
</tr>
<tr>
<td>Other</td>
<td>31 (10)</td>
<td>17 (6)</td>
</tr>
</tbody>
</table>

|          | Pre-PCV7, n = 321   | Post-PCV7, n = 330 |
|          | p value‡             | p value‡             |
|          |                     |                     |
| Controls, n = 296 |                     |                     |
| Vaccinées, n = 324 |                     |                     |
|          | p value‡             | p value‡             |

*Values are no. (%), except as indicated. PCV7, all serotypes included in the 7-valent conjugate vaccine; NA, not applicable; non-PCV7, all other serotypes not included in the 7-valent conjugate vaccine; NT, nontypeable.
†325/329 (99%) swabs were taken just before the booster vaccination at 11 mo of age, and 4/329 (1%) children had received a booster vaccination within 1 wk before the sample was obtained.
‡All p values are for comparison with control group and calculated with χ² or 2-tailed Fisher exact test where appropriate.
§Only non-PCV7 serotypes with >5 isolates in 11- or 24-mo-old children or in parents are included in this table.
¶In only 1 parent, pneumococci were present in both samples but with detection of a different serotype: serotype 19A was found in the transnasal swab and serotype 3 was found in the trnasoral swab. Serotype 19A is included in this table.
‡‡After discrimination between 6A and 6C by PCR, different serotypes were found by PCR compared with Quellung: 3 isolates (serotypes 6B [n = 1] and 14 [n = 2]) in 24-mo-old controls and 2 isolates (serotypes 11 and 15) in 24-mo-old vaccinees. These serotypes were not included in this table.

588

Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 4, April 2011
Carriage of *S. pneumoniae* after Vaccination

did not change, but low carriage rates in adults. Our data are observational, we showed associations and no
both studies, we do not think that the observed carriage
same study procedures were followed by the same well-
makes it harder to detect significant changes. Because the
seasonal variations, and temporal trends could not be taken
into account. Third, the study was not adequately
powered to evaluate serotype-specific differences. Lastly,
used a single-colony method for serotyping in both
studies. Currently, improved techniques for detection of
multisertype carriage, e.g., the newer, more sensitive
PCRs, are available. Multiple serotype carriage methods
might have revealed more nonvaccine strains in both studies,
pointing to unmasking instead of true replacement after eradication of vaccine strains. The strengths of our study
are the relatively high carriage rates found in both studies in
the Netherlands compared with other Western countries, a
high PCV7 uptake in the NIP, and the possibility to evaluate
the effect of vaccination with PCV7 on pneumococcal
carriage in adult contacts. Also, drug-resistant clones do
not confound the results because antimicrobial drug use and
consequent resistance are low in the Netherlands compared
with other European countries (40).

Since 2009, pneumococcal vaccines with broader
coverage have been licensed and will be introduced
into vaccination programs worldwide. The effects of
these broader coverage vaccines on potential shifts in
pneumococcal serotypes in the nasopharynx are still largely
unknown. To predict the long-term health and economic
effects, close monitoring is warranted.

In conclusion, 3 years of vaccination with PCV7
has led to impressive shifts in serotype-specific carriage of *S. pneumoniae* in children and their parents. This
finding indicates a major role of infants in transmission of
pneumococci in the population.

**Acknowledgments**

We thank all members of the research team, the laboratory
staff, and the cooperating institutes for their dedication to this
project. Most of all, we are indebted to all the participating
children and their families, without whom this study would
not have been possible.

This study was funded by the Dutch Ministry of Health.
Grant support for microbiology was provided by Pfizer/Wyeth
Vaccines, the Netherlands, through an unrestricted research grant.

Ms Spijkerman works at the Wilhelmina Children’s Hospital/
University Medical Center Utrecht and the Spaarne Hospital

Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 4, April 2011
Hooftdorp, the Netherlands. Her research interests include determining the effect of pneumococcal conjugate vaccines on nasopharyngeal carriage and immunogenicity to evaluate protection against pneumococcal disease.

References


37. Albrich WC, Baughman W, Schmotzer B, Farley MM. Changing characteristics of invasive pneumococcal disease in metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine. Clin Infect Dis. 2007;44:1569-76. DOI: 10.1086/518149


Address for correspondence: Elisabeth A.M. Sanders, Wilhelmina Children's Hospital, University Medical Center Utrecht, Lundoaan 6, 3508 AB Utrecht, the Netherlands; email: lsanders@umcutrecht.nl

All material published in Emerging Infectious Diseases is in the public domain and may be used and reprinted without special permission; proper citation, however, is required.